- cafead   Mar 28, 2020 at 11:42: PM
via After teasing positive top-line results last November, a deeper dive into Merck & Co. and Bayer’s heart failure drug vericiguat helped kick off this year’s scientific meeting of the American College of Cardiology, presented virtually as a late-breaking trial.
article source
article source